Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors.

Purpose: Circulating tumor cells (CTC) have been recently accepted by the Food and Drug Administration of the United States as a prognostic tool in advanced prostate cancer. However, a number of questions remain about the use of the test. The optimal clinical cut-off has never been determined.